Adma Biologics reported $402.66M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Adma Biologics USD 402.66M 3.1M Sep/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
BioCryst Pharmaceuticals USD 355.68M 42.78M Sep/2025
Minerva Neurosciences USD 13.02M 2.53M Sep/2025
Novavax USD 974.59M 55.08M Sep/2025
Omeros USD 69.65M 26.53M Jun/2025
Takeda JPY 3.12T 195.82B Dec/2025